- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05490030
Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants
A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants
The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155.
The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.
Study Overview
Detailed Description
This is a study to evaluate the PK of TNO155 in participants with mild, moderate or severe hepatic impairment compared to matched healthy control participants with normal hepatic function.
The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment (mild, moderate, or severe) according to a classification score determined at the screening visit and confirmed unchanged at the baseline visit.
Each participant in the healthy control group may be matched to 1 or more evaluable participants with hepatic impairment with respect to age (± 10 years), body weight (± 20%), sex and smoking status (smoker vs. non smoker). Each participant in the control group can be matched to participants from any hepatic impairment group but cannot be matched to more than 1 participant from the same hepatic impairment group.
All participants will be domiciled from Day -1 until Day 11. All participants should have a poststudy safety follow-up contact conducted approximately 30 days after administration of study treatment. The study will be considered complete once all the participants have finished the required assessments, dropped out, or been lost to follow-up before completing the required assessments.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All participants Participants must weigh at least 50 kg and no more than 120 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, for healthy participants. For participants with hepatic impairment without overt ascites, the BMI should be within the range of 18.0 to 40.0 kg/m2. For participants with hepatic impairment with overt ascites, the BMI should be within the range of 18.0 to 45.0 kg/m2.
Group 1
•Each healthy control participant must match in age (± 10 years), sex, body weight (± 20%), and smoking status to at least 1 hepatic impairment participant in Groups 2, 3 and/or 4.
Groups 2 to 4 •Participants with mild, moderate or severe hepatic impairment must have a Child-Pugh score clinically determined at screening and confirmed unchanged at baseline calculated as per the Child-Pugh classification in line with the hepatic impairment status of each Group
Exclusion Criteria:
All Participants
- Use of drugs (prescription, non-prescription and herbal remedies such as St John's wort) known to affect CYP3A or UGT1A3, including UGT1A3 inhibitors and inducers and strong and moderate CYP3A inhibitors and inducers, within 4 weeks prior to dosing until completion of the End of Study Visit.
- Acute or chronic hepatitis B or C infection or active infection requiring therapy that will not be completed before screening.
Left ventricular ejection fraction (LVEF) < 50% or below the institutional standard lower limit, whichever is higher, as determined by multiple gated acquisition (MUGA) scan or Trans-thoracic echocardiography (TTE) at screening or baseline.
•At screening, history of retinal vein occlusion (RVO) or presence of predisposing factors to RVO or central serous retinopathy, or any other clinically significant ophthalmologic abnormalities determined by an ophthalmologist.
Group 1
- Any single parameter of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) exceeding 2.5 × upper limit of normal (ULN) or total bilirubin ≥ 1.5 ULN OR any elevation above ULN of more than 1 parameter of ALT, AST, GGT, ALP, or serum bilirubin at screening or baseline.
- Impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen and/or other urea values outside local laboratory ranges or abnormal urinary constituents at screening or baseline.
Groups 2 and 3
- Severe complications of liver disease within the preceding 3 months prior to dosing.
- Hospitalization due to liver disease within the preceding 1 month prior to dosing.
- Participant has received liver transplant at any time in the past and is on immunosuppressant therapy.
- Participants requiring paracentesis more than every 3 weeks for the management of ascites are excluded.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (control)
Healthy control participants with normal hepatic function
|
Single oral dose of TNO155 on Day 1
|
Experimental: Group 2 (score 5-6)
Mild hepatic impairment: Child-Pugh A
|
Single oral dose of TNO155 on Day 1
|
Experimental: Group 3 (score 7-9)
Moderate hepatic impairment: Child-Pugh B
|
Single oral dose of TNO155 on Day 1
|
Experimental: Group 4 (score 10-15)
Severe hepatic impairment: Child-Pugh C.
This group may be opened if allowed by the results of the interim analysis of the Groups 1 to 3.
|
Single oral dose of TNO155 on Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155
Time Frame: Up to 240 hours post single dose
|
AUClast will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
AUC from time zero to time "t" (AUC0-t) of TNO155
Time Frame: Up to 240 hours post single dose
|
AUC0-t will be calculated as needed based on TNO155 plasma concentrations and non-compartmental methods.
The definition of time "t" may be data-driven post-hoc to mitigate treatment bias due to within participant differences in Tlast between the treatments, or may be selected to allow between-study exposure comparisons that use a common time window.
|
Up to 240 hours post single dose
|
AUC from time zero to infinity (AUCinf) of TNO155
Time Frame: Up to 240 hours post single dose
|
AUCinf will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
Maximum (peak) observed plasma concentration (Cmax) of TNO155
Time Frame: Up to 240 hours post single dose
|
Cmax will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
Time to reach maximum observed plasma concentration (Tmax) of TNO155
Time Frame: Up to 240 hours post single dose
|
Tmax will be calculated based on TNO155 plasma concentrations and non-compartmental methods
|
Up to 240 hours post single dose
|
Elimination half-life (T1/2) of TNO155
Time Frame: Up to 240 hours post single dose
|
T1/2 will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
Sampling time of the last measurable plasma concentration (Tlast) of TNO155
Time Frame: Up to 240 hours post single dose
|
Tlast will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
Apparent plasma clearance (CL/F) of TNO155
Time Frame: Up to 240 hours post single dose
|
CL/F will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
Apparent volume of distribution during terminal phase (Vz/F) of TNO155
Time Frame: Up to 240 hours post single dose
|
Vz/F will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
|
Up to 240 hours post single dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to 30 days post single dose
|
Incidence of AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.
|
Up to 30 days post single dose
|
Unbound Cmax (Cmax,u) of TNO155
Time Frame: Up to 240 hours post single dose
|
Cmax,u will be calculated based on the unbound fraction of TNO155 in plasma.
|
Up to 240 hours post single dose
|
Unbound AUClast (AUClast,u) of TNO155
Time Frame: Up to 240 hours post single dose
|
AUClast,u will be calculated based on the unbound fraction of TNO155 in plasma.
|
Up to 240 hours post single dose
|
Unbound AUCinf (AUCinf,u) of TNO155
Time Frame: Up to 240 hours post single dose
|
AUCinf,u will be calculated based on the unbound fraction of TNO155 in plasma
|
Up to 240 hours post single dose
|
Unbound CL/F (CL/F,u) of TNO155
Time Frame: Up to 240 hours post single dose
|
CL/F,u will be calculated based on the unbound fraction of TNO155 in plasma.
|
Up to 240 hours post single dose
|
Renal clearance (CLr) of TNO155
Time Frame: Up to 240 hours post single dose
|
CLr will be calculated based on urinary excretion data of TNO155.
|
Up to 240 hours post single dose
|
Apparent non-renal clearance (CLNR/F) of TNO155
Time Frame: Up to 240 hours post single dose
|
CLNR/F will be calculated based on urinary excretion data of TNO155.
|
Up to 240 hours post single dose
|
Fraction of dose excreted in urine (fe) of TNO155
Time Frame: Up to 240 hours post single dose
|
Fe will be calculated based on urinary excretion data of TNO155.
|
Up to 240 hours post single dose
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTNO155A12106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Impairment
-
PfizerRecruitingHealthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
-
GlycoMimetics IncorporatedCompletedModerate Hepatic Impairment | Normal Hepatic FunctionUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedSevere Hepatic Impairment | Normal Hepatic FunctionBulgaria
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
-
EQRx International, Inc.CompletedSevere Hepatic ImpairmentUnited States
-
PfizerCompleted
-
TakedaCompletedSevere Hepatic ImpairmentUnited States
-
Bausch Health Americas, Inc.TerminatedSevere Hepatic ImpairmentUnited States
-
KBP BiosciencesCovanceCompletedHealthy | Moderate Hepatic ImpairmentUnited States
Clinical Trials on TNO155
-
Novartis PharmaceuticalsPharmaceutical Research AssociatesWithdrawn
-
Novartis PharmaceuticalsRecruitingAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MelanomaNetherlands, Korea, Republic of, Spain, Taiwan, Japan, Italy, Canada, United States, Singapore
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, ColorectalUnited States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
-
Mirati Therapeutics Inc.NovartisActive, not recruitingMetastatic Cancer | Advanced Cancer | Malignant Neoplastic DiseaseUnited States
-
Novartis PharmaceuticalsTerminatedColorectal Cancer | Gastrointestinal Stromal Tumors | Non-small Cell Lung Carcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal SCCUnited States, Germany, Spain, Singapore, Australia, Hong Kong, Belgium, Japan, China
-
Massachusetts General HospitalPfizer; Array BioPharmaRecruitingNSCLC | Lung Cancer | Relapsed Cancer | Resistant Cancer | MET Amplification | Anaplastic Lymphoma Kinase Gene Translocation | ROS1 RearrangementUnited States
-
Novartis PharmaceuticalsActive, not recruitingBRAF V600 Colorectal CancerBelgium, Germany, Netherlands, Spain, Singapore, Australia, United Kingdom, Israel, Canada, United States
-
AmgenRecruitingAdvanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada